|
Delayed
TEL AVIV STOCK EXCHANGE
08:08:21 24/09/26 pm AEST
|
5-day change | 1st Jan Change | ||
| 1,678.00 ILa | -0.12% |
|
+3.01% | +3.71% |
| 09/09 | InterCure Regains Nasdaq Compliance | MT |
| 25/08 | InterCure Ltd. announced that it has received ILS 21.711643 million in funding from Bennu Pharma Fund Ltd and other investors. | CI |
Main competitors
| Revenues (Y-1) | Net Margin (Y-1) | EBIT Margin (Y-1) | ROE (Y-1) | ROA (Y-1) | Leverage (Y-1) | ||
|---|---|---|---|---|---|---|---|
 | 157M | 15.02% | - | - | - | -0.85x | |
| 186M | -9.55% | -5.9% | - | - | - | |
| 78.12M | 12.18% | 20.68% | - | - | - | |
| 501M | -23.61% | -3.4% | -661.87% | -8.62% | 1.85x | |
| Average | 231M | -1.49% | 3.79% | -661.87% | -8.62% | 0.50x | |
| Weighted average by Cap. | 198M | 4.05% | 4.28% | -661.87% | -8.62% | -0.21x |
- Stock Market
- Stocks
- INCR Stock
- Sector InterCure Ltd.
- Financial comparisons
Select your edition
All financial news and data tailored to specific country editions
